证券代码：300261 证券简称：雅本化学 公告编号：2025-084 雅本化学股份有限公司 | | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 占其 | 占公 | 情况 | | 情况 | | | 股东名 | 持股数量 | 持股 | 本次质押前 | 本次质押后 | 所持 | 司总 | 已质押股 | 占已 | 未质押股 | 占未 | | | | 比例 | 质押股份数 | 质押股份数 | 股份 | | | 质押 | | 质押 | | 称 | （股） | (%) | 量 | 量 | 比例 | 股本 | 份限售和 | 股份 | 份限售和 | 股份 | | | | | | | (%) | 比例 | 冻结数量 | 比例 | 冻结数量 | 比例 | | | | | | | | | （股） | (%) | （股） | (%) | | 宁波雅 本控股 | | | | | | | | | | | | 有限公 | 257,729,839 | 26.75 ...

一、担保情况概述 2025 年 1 月 24 日，雅本化学股份有限公司（以下简称"公司"）第五届 董事会第二十三次（临时）会议和第五届监事会第二十二次（临时）会议审议 通过了《关于公司为子公司提供担保及子公司互相担保的议案》。为满足子公 司的经营发展需要，公司同意为全资子公司上海雅本化学有限公司（以下简称 "上海雅本"）、南通雅本化学有限公司（以下简称"南通雅本"）、江苏建 农植物保护有限公司（以下简称"建农植保"）办理银行授信等业务提供担保。 具体内容详见公司于 2025 年 1 月 25 日在巨潮资讯网上披露的《关于公司为子 公司提供担保及子公司互相担保的公告》（公告编号：2025-008）。2025 年 2 月 24 日，公司 2025 年第一次临时股东大会审议通过了上述议案。 2025 年 6 月 16 日，公司第六届董事会第四次（临时）会议和第六届监事 会第四次（临时）会议审议通过了《关于全资子公司向银行申请项目贷款并由 公司提供担保的议案》，公司同意为南通雅本申请银行项目贷款提供担保，担 保方式为连带责任保证担保，额度不超过人民币 2,500 万元，借款期限不超过 36 个月，主要用于支付项目建设 ...

证券日报网讯 12月19日晚间，雅本化学发布公告称，公司2025年第四次临时股东会审议通过《关于增 加2025年度担保额度及担保对象的议案》。 （文章来源：证券日报） ...

一、会议召开和出席情况 雅本化学股份有限公司（以下简称"公司"）2025 年第四次临时股东会（以 下简称"股东会"）现场会议于 2025 年 12 月 19 日下午 14:30 在上海市浦东新 区新环南路 289 号二楼会议室召开；同时使用深圳证券交易所交易系统网络投票 于 2025 年 12 月 19 日交易时间接受网络投票，即 9:15-9:25，9:30-11:30 和 13:00-15:00；使用深圳证券交易所互联网投票系统于 2025 年 12 月 19 日上午 9:15 至下午 15:00 期间接受网络投票。 出席本次股东会的股东及股东的委托代理人共计 355 人，代表有表决权的股 份数为 268,415,419 股，占公司股份总数的 27.8639％。其中，参加现场会议的股 东及股东代表 3 人，代表股份 258,760,141 股，占公司股份总数的 26.8616％；参 加网络投票的股东及股东代表 352 人，代表股份 9,655,278 股，占公司股份总数 的 1.0023％。 证券代码：300261 证券简称：雅本化学 公告编号：2025-082 雅本化学股份有限公司 2025 年第四次临 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于雅本化学股份有限公司 国枫律股字[2025]A0619 号 致：雅本化学股份有限公司（"贵公司"或"雅本化学"） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2025 年第四次临时股东会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《律师事务所从事证券法律业务管理 办法》（以下简称"《证券法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试 行）》（以下简称"《证券法律业务执业规则》"）等相关法律、行政法规、规章、规范性 文件及《雅本化学股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会 议的召集与召开程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事 宜，出具本法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 1．本所律师仅就本次会议的召集与召开 ...

Group 1 - The core point of the article is that Yabao Chemical has reported a total of 53,905 shareholders as of December 10, 2025 [2]

Core Insights - The article highlights the journey and achievements of Cai Tong, the founder of Yabao Chemical, emphasizing his unique interdisciplinary background and strategic vision in the fine chemical industry [2][3]. Company Development - Yabao Chemical has focused on deepening its core business layout, particularly in the pharmaceutical sector, by signing a strategic cooperation agreement with leading domestic pharmaceutical company Heng Rui Medicine to enhance the quality and efficiency of its pharmaceutical business [3]. - The company has established its Malta base as a bridge for international business, equipped with EU GMP certification and formulation repackaging capabilities, facilitating domestic pharmaceutical companies' expansion into overseas markets [3]. - In the agrochemical intermediate sector, Yabao Chemical is concentrating on innovative, green, and efficient CDMO services, maintaining strategic partnerships with international agrochemical firms such as Corteva, Bayer, and FMC to solidify its leading position in niche markets [3]. Innovation and Investment - During the 14th Five-Year Plan period, Yabao Chemical has invested nearly 600 million yuan in research and development, prioritizing technological innovation as a core growth engine and establishing an AI research laboratory to build an intelligent R&D system [3]. - The company aims to create a diversified business structure encompassing pharmaceuticals, agrochemicals, and other sectors, referred to as "Pharmaceuticals + Agrochemicals + X" [3]. Recognition and Contributions - Cai Tong has received various accolades for his contributions to the industry and society, including the 2010 Taicang City First Lou Dong Talent Award and the 2013 Outstanding Person in China's Service Outsourcing Award [4]. - He holds multiple positions in educational and industry associations, contributing to talent cultivation and regional industrial collaboration [4].

Core Insights - The company, Yabao Chemical, was founded by Cai Tong, who leveraged his interdisciplinary knowledge in chemistry and economics to establish a unique position in the fine chemical industry [2][3] - Yabao Chemical has focused on the CDMO (Contract Development and Manufacturing Organization) segment in fine chemicals, particularly in innovative pharmaceuticals and agrochemicals, leading to its successful listing on the capital market [2][3] Business Development - Yabao Chemical has deepened its core business layout, particularly in the pharmaceutical sector, by signing a strategic cooperation agreement with leading domestic pharmaceutical company, Hengrui Medicine, to enhance the quality and efficiency of its pharmaceutical business [3] - The company’s Malta base serves as a bridge for international business, equipped with EU GMP certification and formulation repackaging capabilities, facilitating domestic pharmaceutical companies' expansion into overseas markets [3] - In the agrochemical intermediate sector, Yabao Chemical focuses on green, efficient, and low-toxicity innovative agrochemical CDMO business, maintaining strategic partnerships with international agricultural companies such as Corteva, Bayer, and FMC [3] Innovation and Investment - During the 14th Five-Year Plan period, Yabao Chemical has invested nearly 600 million yuan in research and development, positioning technology innovation as its core development engine [3] - The company has established an AI research and development laboratory to build an intelligent R&D system, solidifying its technological advantages in the industry [3] Recognition and Contributions - Cai Tong has received various accolades for his contributions to the industry and society, including the 2010 Taicang City First Lou Dong Talent Award and the 2013 Outstanding Person in China's Service Outsourcing Award [4] - He holds multiple positions, including a board member at Fudan University and vice president of the Fudan University Chemistry Alumni Association, contributing to talent cultivation and regional industrial collaboration [4]

Core Insights - The company, Yabao Chemical, has established itself as a leader in the fine chemical sector by focusing on technology-driven and core business strategies, particularly in the CDMO segment for innovative pharmaceuticals and agrochemicals [1][2]. Group 1: Company Background - Founded by Cai Tong, Yabao Chemical has leveraged a unique combination of expertise in chemistry and economics to navigate the fine chemical industry [1]. - The company has successfully listed on the capital market, becoming a benchmark in the domestic fine chemical field [1]. Group 2: Business Development - Yabao Chemical has intensified its core business layout, particularly in the pharmaceutical sector, by signing strategic cooperation agreements with leading domestic pharmaceutical companies like Heng Rui Medicine, focusing on key areas such as oncology and cardiovascular diseases [2]. - The Malta base serves as an international business hub with EU GMP certification, facilitating domestic pharmaceutical companies' expansion into overseas markets [2]. - In the agrochemical sector, the company emphasizes green, efficient, and low-toxicity innovative CDMO services, maintaining strategic partnerships with international firms like Corteva, Bayer, and FMC [2]. Group 3: Innovation and Investment - During the 14th Five-Year Plan period, Yabao Chemical has invested nearly 600 million yuan in research and development, prioritizing technological innovation as a core growth engine [2]. - The establishment of an AI research laboratory reflects the company's commitment to building an intelligent R&D system, solidifying its technological advantages in the industry [2]. Group 4: Recognition and Contributions - Cai Tong has received various accolades for his contributions to the industry and society, including the 2010 Taicang City First Lou Dong Talent Award and the 2013 Outstanding Person in China's Service Outsourcing Award [3]. - He holds multiple positions in educational and industry associations, contributing to talent cultivation and regional industrial collaboration [3].

Core Viewpoint - The company indicates that the change in gross margin for pharmaceutical intermediates in 2024 is primarily due to adjustments in product structure [1] Group 1 - The company will provide relevant data regarding the gross margin for pharmaceutical intermediates in 2025 in future periodic reports [1] - The company emphasizes its commitment to fulfilling information disclosure obligations in accordance with legal regulations [1]